DURECT Corp. and Zogenix Inc. terminated a 2011 agreement to develop and commercialize a psychosis treatment.

Zogenix completed several phase 1 clinical trials for the investigational drug Relday and reported that it was generally safe and well-tolerated.

The company returned development and commercialization rights to Durect and will also transfer all regulatory filings and development information.